Pharming Group N.V. (PHAR) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 25, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PHAR SEC filings page.
Pharming Group N.V. (PHAR) reported $376.1M in revenue for fiscal year 2025, up 26.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash conversion became the dominant mechanic as revenue expanded, with FY2025 operating cash flow far exceeding reported net income.
Net margin returned to0.7% in FY2025, yet operating cash flow reached14.5% of revenue; the business converted sales into cash far more effectively than its income statement suggests. With free-cash-flow margin at14.3% , that cash result was not mainly consumed by reinvestment, although it does not establish equivalent recurring earnings.
Revenue expanded
The balance sheet changed shape in FY2025: goodwill rose from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Pharming Group N.V.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Pharming Group N.V., and counted as zero in the overall score.
Pharming Group N.V.'s revenue surged 26.6% year-over-year to $376.1M, reflecting rapid business expansion. This strong growth earns a score of 85/100.
Pharming Group N.V. carries a low D/E ratio of 0.05, meaning only $0.05 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 84/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.59, Pharming Group N.V. holds $2.59 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 72/100.
Pharming Group N.V. has a free cash flow margin of 14.3%, earning a moderate score of 47/100. The company generates positive cash flow after capital investments, but with room for improvement.
Not available for Pharming Group N.V., and counted as zero in the overall score.
Pharming Group N.V. passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Pharming Group N.V. reported $2.5M of net income while generating $54.7M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Pharming Group N.V. held $145.3M in cash against $14.4M in long-term debt as of Q4 2025.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
PHAR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
PHAR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q4'2420-F | Q4'2310-K | Q4'2210-K | Q4'2110-K | Q4'2010-K | Q4'1910-K |
|---|---|---|---|---|---|---|---|
| Total Assets | $500.0M+25.0% | $400.0M-13.6% | $462.9M+8.7% | $425.8M+7.2% | $397.3M-5.1% | $418.5M+63.5% | $255.9M |
| Current Assets | $299.5M+7.6% | $278.4M-12.0% | $316.3M+14.0% | $277.5M+11.2% | $249.4M-5.2% | $263.2M+120.4% | $119.4M |
| Cash & Equivalents | $145.3M+164.5% | $54.9M-11.0% | $61.7M-70.2% | $207.3M+8.0% | $191.9M-6.5% | $205.2M+175.9% | $74.3M |
| Inventory | $64.9M+16.5% | $55.7M-1.8% | $56.8M+34.1% | $42.3M+55.0% | $27.3M+29.1% | $21.2M+30.4% | $16.2M |
| Accounts Receivable | $54.7M-0.2% | $54.8M+18.8% | $46.2M+67.1% | $27.6M-7.9% | $30.0M-16.5% | $35.9M+24.4% | $28.9M |
| Goodwill | $135.5M+122.1% | $61.0M-14.4% | $71.3M | N/A | N/A | N/A | N/A |
| Total Liabilities | $222.9M+24.6% | $178.9M-26.7% | $244.1M+10.4% | $221.2M+8.2% | $204.4M-13.0% | $235.0M+69.7% | $138.5M |
| Current Liabilities | $115.8M+56.9% | $73.8M-5.3% | $78.0M+30.6% | $59.7M+27.6% | $46.8M-39.1% | $76.8M-32.7% | $114.3M |
| Non-Current Liabilities | $107.1M+1.9% | $105.1M-36.7% | $166.1M+2.9% | $161.5M+2.4% | $157.6M-0.3% | $158.2M+551.6% | $24.3M |
| Long-Term Debt | $14.4M-46.8% | $27.0M-8.6% | $29.5M-1.1% | $29.8M+61.7% | $18.5M+124.3% | $8.2M+68.2% | $4.9M |
| Total Equity | $277.1M+25.4% | $221.1M+1.0% | $218.8M+6.9% | $204.6M+6.1% | $192.9M+5.2% | $183.4M+56.3% | $117.4M |
| Retained Earnings | -$273.0M+0.9% | -$275.5M-3.9% | -$265.3M-3.4% | -$256.4M+6.1% | -$273.2M+7.6% | -$295.6M+13.2% | -$340.7M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
PHAR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
PHAR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Pharming Group N.V. PHAR | FY2025 | $376.1M | $2.5M | 0.7% | $738.9M | 48/100 |
| Rapport Therapeutics, Inc. RAPP | FY2025 | N/A | -$111.5M | N/A | $1.6B | — |
| Sionna Therapeutics, Inc. SION | FY2025 | N/A | -$75.3M | N/A | $249.1M | — |
| CorMedix Inc. CRMD | FY2025 | $311.7M | $163.1M | 52.3% | $599.4M | 50/100 |
| Maravai LifeSciences Holdings, Inc. MRVI | FY2025 | $185.7M | -$130.8M | -70.4% | $1.1B | 24/100 |
| ARS Pharmaceuticals, Inc. SPRY | FY2025 | $84.3M | -$171.3M | N/A | $415.7M | 51/100 |
Where Pharming Group N.V. Ranks
Frequently Asked Questions
What is Pharming Group N.V.'s annual revenue?
Pharming Group N.V. (PHAR) reported $376.1M in total revenue for fiscal year 2025. This represents a 26.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Pharming Group N.V.'s revenue growing?
Pharming Group N.V. (PHAR) revenue grew by 26.6% year-over-year, from $297.2M to $376.1M in fiscal year 2025.
Is Pharming Group N.V. profitable?
Yes, Pharming Group N.V. (PHAR) reported a net income of $2.5M in fiscal year 2025, with a net profit margin of 0.7%.
How much debt does Pharming Group N.V. have?
As of fiscal year 2025, Pharming Group N.V. (PHAR) had $145.3M in cash and equivalents against $14.4M in long-term debt.
What is Pharming Group N.V.'s net profit margin?
Pharming Group N.V. (PHAR) had a net profit margin of 0.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Pharming Group N.V.'s return on equity (ROE)?
Pharming Group N.V. (PHAR) has a return on equity of 0.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Pharming Group N.V.'s free cash flow?
Pharming Group N.V. (PHAR) generated $54.0M in free cash flow during fiscal year 2025. This represents a 2187.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Pharming Group N.V.'s operating cash flow?
Pharming Group N.V. (PHAR) generated $54.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Pharming Group N.V.'s total assets?
Pharming Group N.V. (PHAR) had $500.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Pharming Group N.V.'s capital expenditures?
Pharming Group N.V. (PHAR) invested $749K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Pharming Group N.V.'s current ratio?
Pharming Group N.V. (PHAR) had a current ratio of 2.59 as of fiscal year 2025, which is generally considered healthy.
What is Pharming Group N.V.'s debt-to-equity ratio?
Pharming Group N.V. (PHAR) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Pharming Group N.V.'s return on assets (ROA)?
Pharming Group N.V. (PHAR) had a return on assets of 0.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Pharming Group N.V.'s P/E ratio?
Pharming Group N.V. (PHAR) trades at 291x earnings, its market capitalization divided by net income of $2.5M net income, FY2025. The market capitalization is $738.9M as of Sep 25, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Pharming Group N.V.'s price-to-sales ratio?
Pharming Group N.V. (PHAR) trades at 2.0x sales, its market capitalization divided by revenue of $376.1M revenue, FY2025. The market capitalization is $738.9M as of Sep 25, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Pharming Group N.V.'s Piotroski F-Score?
Pharming Group N.V. (PHAR) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pharming Group N.V.'s earnings high quality?
Pharming Group N.V. (PHAR) reported $2.5M of net income while generating $54.7M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Pharming Group N.V.?
Pharming Group N.V. (PHAR) scores 48 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.